U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07452744) titled 'Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease' on Jan. 30.
Brief Summary: This is a Phase III, multicentre, randomized, double-blind, placebo-controlled, interventional study designed to evaluate the efficacy and safety of a standardized fraction of Picrorhiza kurroa Royal Ex Benth (Picroliv(R)) in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
A total of 170 adults aged 18-60 years with uncomplicated NAFLD (fibrosis stage up to F2) will be randomized in a 2:1 ratio to receive either Picroliv 100 mg capsules twice daily or matching placebo, in addition to standard of care, for a treatmen...